Join MyFreeStyle and get your first sensor for FREE* Find out more.

  

|

Know the proven outcomes - Now you know

Know the proven outcomes - Now you know

FreeStyle Libre has been clinically shown to help reduce HbA1c in people living with T1D and Insulin-requiring T2D12,27,28

Type 1 diabetes

A1c inside a circle next to a blue downwards arrow showing a decrease of 0.53 percent.

After 12-16 weeks

In adults with T1D using FreeStyle Libre (p<0.0001 vs. baseline)12

Type 2 diabetes

A1c inside a circle next to a wide blue downwards arrow showing a decrease of 0.82 percent.

After 10 weeks

*In people with T2D on multiple daily injections of insulin and FreeStyle Libre (p=0.005 vs. standard blood glucose monitoring)28

A1c inside a circle next to a wide blue downwards arrow showing a decrease of 1.1 percent.

After 22 weeks

**In people with T2D who were using basal insulin and FreeStyle Libre (p<0.001 vs. baseline A1c)27

Lowering HbA1c reduces your risk of diabetes related complications

FreeStyle Libre has been shown to help reduce hypos in insulin-using people with both T1D and T2D6,17

Type 1 diabetes

The word Hypo inside a circle next to a wide blue downwards arrow showing a decrease of 38 percent.

After 6 months

less time spent in hypo in people with T1D

(p=0.0001 vs. standard blood glucose monitoring)6

A 6-month RCT in 328 well-controlled T1D patients (with baseline A1c ≤7.5%) proves the FreeStyle Libre system safely and successfully replaces SMBG.6

Type 2 diabetes

The word Hypo inside a circle next to a wide blue downwards arrow showing a decrease of 43 percent.

After 6 months

less time spent in hypo in people with T2D

(p=0.0006 vs. standard blood glucose monitoring)17

A 6-month RCT in 224 T2D patients on intensive insulin therapy proves the FreeStyle Libre system safely and successfully replaces SMBG.17

A reduction in hypoglycemic episodes could help you enjoy a better quality of life13 and reduce diabetes-related hospital admissions.10

Abbreviations: A1c: glycated haemoglobin; hypo: hypoglycemic event; RCT: randomised controlled trial; SMBG: self-monitoring of blood glucose; T1D: type 1 diabetes; T2D: type 2 diabetes.

References: 6. Bolinder J, et al. Lancet. 2016;388(10057):2254-2263. 10. Charleer S, et al. Diabetes Care 2020;43(2):389-397. 12. Evans M, et al. Diabetes Ther 2022. https://doi.org/10.1007/s13300-022-01253-9. 13. Fokkert M, et al. BMJ Open Diab Res Care 2019;7(1):e000809. 17. Haak T, et al. Diabetes Therapy 2017;8:55-73. 27. Wright E, et al. Diabetes Spectrum. 2021;34(2):184–189. 28. Yaron, M. Diabetes Care 2019;42(7):1178–1184.